靶向治疗对复发性耐药性卵巢癌的治疗价值

doi:10.7504/fk2015020108

摘要/Abstract

摘要：

卵巢癌复发率高，预后差，多数患者在反复间断化疗后最终都会出现耐药。近年来靶向药物在复发性耐药性卵巢癌的临床试验中取得了较为可喜的结果。广泛研究的靶向药物有血管内皮生长因子受体抑制剂如贝伐单抗，DNA损伤修复抑制剂如奥拉帕尼、Veliparib，血管生成素抑制剂如Trebananib，叶酸受体抑制剂如Vintafolide等等。近期研究显示，这些药物可延长铂耐药卵巢癌患者的无疾病间期。其中贝伐单抗联合单药化疗是目前临床应用较为成熟的治疗方案。文章重点介绍靶向治疗在复发性耐药性卵巢癌临床研究中的最新进展。

关键词: 靶向治疗, 卵巢肿瘤, 耐药, 复发

Abstract:

Abstract:Ovarian cancer is noted for high recurrence and poor prognosis.Drug-resistance will eventually appear after repeated intermittent chemotherapy by most patients.There are a number of promising results of targeted therapy in recent clinical trials for patients with platinum-resistant OC.Drugs in extensive research include vascular endothelial growth factor inhibitor,such as Bevacizumab,DNA repair inhibitor,such as Olaparib and Veliparib,angiogenin inhibitor,such as Trebananib,and folate receptor inhibitor,such as Vintafolide,et al.These drugs have recently shown to improve progression-free survival of patients with platinum-resistant OC.Bevacizumab in combination with single-agent chemotherapy was considered as preferred treatment.In this review,the latest developments of targeted therapy in the platinum-resistant recurrent OC are highlighted.

Key words: targeted therapy, ovarian cancer, platinum-resistance, recurrent

中图分类号:

R737.3

白萍，舒桐，孙慧. 靶向治疗对复发性耐药性卵巢癌的治疗价值[J]. 中国实用妇科与产科杂志, DOI: 10.7504/fk2015020108.

BAI Ping,SHU Tong,SUN Hui.. The therapeutic role of targeted therapy in the treatment for recurrent platinum-resistant ovarian cancer.[J]. Acta Metallurgica Sinica, DOI: 10.7504/fk2015020108.

参考文献

［1］   Hennessy BT,Coleman RL,Markman M.Ovarian cancer［J］.Lancet,2009,374(9698): 1371-1382.

［2］   Burger RA,Brady MF,Bookman MA,et al.Incorporation of bevacizumab in the primary treatment of ovarian cancer［J］.N Engl J Med,2011,365: 2473-2483.

［3］    Perren TJ,Swart AM,Pfistrer J,et al.A phase 3 trial of bevacizumab in ovarian cancer［J］.N Engl J Med,2011,365: 2484-2496.

［4］   Aghajanian C,Blank SV,Goff BA,et al.OCEANS: a randomized,double blind placebo-controlled phase Ⅲ trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian,primary peritoneal,or fallopian tube cancer［J］.J Clin Oncol,2012，30: 2039-2045.

［5］   Pujade-Lauraine E,Hilpert F,Weber B,et al.Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase Ⅲ trial［J］.J Clin Oncol,2014，32(13): 1302-1308.

［6］   William PT,Michael SD，Scott M,et al.A randomized phase Ⅱ trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC),fallopian tube (FTC),or primary peritoneal cancer (PPC) ［J］.J Clin Oncol，2014，32:5(suppl; abstr5546).

［7］   Huichung TL,Franco M,James LS,et al.A phase Ⅱ trial on the combination of bevacizumab and irinotecan in recurrent ovarian cancer［J］.J Clin Oncol，2014，32:5s(suppl; abstr5564)

［8］   Tillmanns TD,Lowe MP,Walker MS,et al.Phase Ⅱ clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent,platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma［J］.Gynecol Oncol,2013，128(2): 221-228.

［9］   Huang H,Zheng Y,Zhu J,et al.An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients［J］.PLoS One，2014，9 :e89960.

［10］   Qi WX,Shen Z,Tang LN,et al.Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups［J］.Eur J Clin Pharmacol，2014，70(8):893-906.

［11］   Ccoleman RL,Sill M,Aghajaian C,et al.A phase Ⅱ evaluation of the potent,highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian,fallopian tube,or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation- a Gynecologic Oncology Group study(A),Society of Gynecologic Oncology 45th Annual Meeting on Women’s Cancer(C).2014.

［12］    Fong PC,Yap TA,Boss DS,et al.Poly (ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval［J］.J Clin Oncol，2010，28(15): 2512-2519.

［13］    Audeh MW,Carmichael J,Penson RT,et al.Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial［J］.Lancet，2010，376(97,37):245-251.

［14］   Birrer MJ,Konstantinopoulos P,Penson RT,et al.A phase Ⅱ trial of iniparib(BSI-201) in combination with gemcitabine/carboplatin(GC) in patients with platinum-resistant recurrent ovarian cancer［J］.J Clin Oncol，2011，29(Suppl):5005.

［15］   du Bois A,Floquet A,Kim JW,et al.Incorporation of pazopanib in maintenance therapy of ovarian cancer［J］.J Clin Oncol，2014，32(30):3374-3382.

［16］    Pignata S,Lorusso D, Scambia G,et al.MITO-11:a randomized multicenter phase II trial testing the addition of pazopanib to weekly paclitaxel in platinum-resistant or -refractory advanced ovarian cancer (AOC) ［J］.J Clin Oncol,2014,32:5s(suppl; abstr 5503^).

［17］   Monk BJ,Poveda A,Vergote I,et al.Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised,multicentre,double-blind,placebo-controlled phase 3 trial［J］.Lancet Oncol,2014,15(8): 799-808.

［18］   Penson RT,Moore KM,Fleming GF,et al.A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian,fallopian tube or primary peritoneal carcinoma［J］.Gynecol Oncol，2014，134(3):478-485.

［19］   Gordinier ME,Dizon DS,Weitzen S,et al.Oral thalidomide as palliative chemotherapy in women with advanced ovarian cancer［J］.J Palliat Medc,2014，10(1): 61-66.

［20］    De Geest K,Blessing JA,Morris RT,et al.Phase II clinical trial of ixabepilone in patients with recurrent or persistnet platinum and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study［J］.J Clin Oncol，2010，28(1);149-153.

［21］    McNeish IA,Ledermann JA,Webber L,et al.A randomised,placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian,fallopian tube or primary peritoneal cancer［J］.Ann Oncol,2014，25(10): 1988-1995.

（2014-11-15收稿）

[1]	郎景和. 关于妇科复发性疾病与疑难性疾病的若干问题[J]. 中国实用妇科与产科杂志, 2022, 38(5): 481-483.
[2]	张师前. 聚焦关键少数，做好塔尖工作[J]. 中国实用妇科与产科杂志, 2022, 38(5): 484-486.
[3]	王辰, 王颖梅, 薛凤霞. 复发性外阴阴道假丝酵母菌病的预防与治疗[J]. 中国实用妇科与产科杂志, 2022, 38(5): 487-491.
[4]	彭超, 周应芳. 复发性卵巢子宫内膜异位症的管理[J]. 中国实用妇科与产科杂志, 2022, 38(5): 491-495.
[5]	鲁永鲜. 盆腔器官脱垂手术复发的预防与治疗[J]. 中国实用妇科与产科杂志, 2022, 38(5): 495-499.
[6]	谢鹏, 郭秋芬, 张师前. 复发性子宫颈癌的综合治疗[J]. 中国实用妇科与产科杂志, 2022, 38(5): 499-503.
[7]	李一帆, 李宁, 吴令英. 铂耐药复发卵巢上皮性癌的治疗[J]. 中国实用妇科与产科杂志, 2022, 38(5): 503-507.
[8]	徐兴远, 王丹波. 复发性子宫内膜癌的治疗[J]. 中国实用妇科与产科杂志, 2022, 38(5): 507-511.
[9]	万书婷, 王谢桐, . 子宫动脉血流监测在产科的应用[J]. 中国实用妇科与产科杂志, 2022, 38(4): 403-406.
[10]	曹冬焱, 向阳. 卵巢癌手术质量控制[J]. 中国实用妇科与产科杂志, 2022, 38(1): 29-32.
[11]	张国楠, 石宇, 王登凤. 助力实现R0，减少铂耐药的发生——晚期卵巢癌广泛性壁层腹膜切除术的临床意义[J]. 中国实用妇科与产科杂志, 2022, 38(1): 9-12.
[12]	中国医院协会妇产医院分会妇科肿瘤专业学组. 预防性输卵管切除术的中国专家共识（2021年版）[J]. 中国实用妇科与产科杂志, 2021, 37(8): 826-831.
[13]	李宁，吴令英. 中国临床肿瘤学会《卵巢癌诊疗指南（2021年版）》更新要点[J]. 中国实用妇科与产科杂志, 2021, 37(7): 720-723.
[14]	陈雨莲，史庭燕，臧荣余. 铂敏感复发卵巢癌手术相关问题与规范化诊疗[J]. 中国实用妇科与产科杂志, 2021, 37(6): 616-620.
[15]	王登凤，张国楠. 卵巢癌靶向治疗的规范化[J]. 中国实用妇科与产科杂志, 2021, 37(6): 634-639.